Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 7
Diabetes care
+3%
Sales growth derived from diabetes care and obesity,
driven by Tresiba®, VictozaⓇ and SaxendaⓇ
Sales as reported – full year 2017
Growth
Other
hormone biopharmaceuticals
Haemophilia 6%
(24%)
0%
9%
Obesity
2%
+62%
(53%)
%
Growth analysis - full year 2017
Local currencies
New-generation insulin¹
Modern insulin
Human insulin
VictozaⓇ
Growth
Share of growth
98%
173%
(4%)
(76%)
(7%)
(29%)
18%
140%
Other diabetes care²
(3%)
(5%)
Total diabetes care
6%
203%
Obesity (SaxendaⓇ)
64%
40%
81%
Diabetes care and obesity total
7%
243%
Haemophilia³
2%
7%
Growth disorders
(22%)
(76%)
Sales of DKK 111.7 billion (0%)
Other biopharmaceuticals4
(52%)
(74%)
changing
diabetes
Biopharmaceuticals
Total
1 Comprises TresibaⓇ, Xultophy®, RyzodegⓇ and FiaspⓇ
2 Primarily Novo NormⓇ and needles
3 Comprises NovoSeven®, Novo Eight® NovoThirteenⓇ and Refixia®
4 Primarily Vagifem® and Activelle®
(16%)
(143%)
2%
100%View entire presentation